Big Phar­ma has skirt­ed long Covid, but a pipeline of small biotechs is test­ing treat­ments for lin­ger­ing symp­toms

Long Covid has been part­ly mys­te­ri­ous, due to the nascen­cy of SARS-CoV-2 as well as the vast­ness of lin­ger­ing symp­toms ex­pe­ri­enced by mil­lions of peo­ple world­wide fol­low­ing their ini­tial di­ag­noses.

That makes long Covid quite a wide um­brel­la term and has led to a large gap in R&D, as it ap­pears there’s a gen­er­al un­will­ing­ness of most bio­phar­mas to con­sid­er test­ing their drugs in this con­di­tion. For the most part, drug­mak­ers in­ter­est­ed in Covid-19 have most of their eggs in the pre­ven­tion and acute treat­ment bas­kets through vac­cines, mon­o­clon­al an­ti­bod­ies and an­tivi­rals.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.